Biocept to Present at 2015 Aegis Growth Conference

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the 2015 Aegis Growth Conference on October 9, 2015 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). The conference is being held at The Encore at Wynn Las Vegas hotel in Las Vegas.

A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term. For additional information, please visit www.biocept.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005020/en/

Investor Contact:
LHA
Jody Cain
310-691-7100
[email protected]

Source: Biocept, Inc.

You May Also Be Interested In

• FDA Roundup: April 16, 2024
• Picton Mahoney Asset Management Announces Monthly Distribution for Picton Mahoney Fortified Income Alternative Fund Exchange Traded Fund Units, Picton Mahoney Fortified Special Situations Alternative
• Cencia Exchange has purchased commercial insurance for liquidation, providing cash claim protection for Cencia users